Profile data is unavailable for this security.
About the company
China Traditional Chinese Medicine Holdings Co. Limited is principally engaged in the manufacture and sales of traditional Chinese medicine (TCM). The Company operates through 12 subsidiaries, including Sinopharm Group Dezhong (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Guangdong Medi-World Pharmaceutical Co., Ltd., Sinopharm Group Luya (Shandong) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Medicinal Material & Slices Co., Ltd., Foshan Winteam Pharmaceutical Sales Company Limited, Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Sinopharm Group Jingfang (Anhui) Pharmaceutical Co., Ltd., Sinopharm Group Longlife (Guizhou) Pharmaceutical Co., Ltd., Qinghai Pulante Pharmaceutical Co., Ltd., Guizhou Zhongtai Biological Technology Company Limited and its subsidiaries and Jiangyin Tianjiang Pharmaceutical Co., Ltd. and its subsidiaries.
- Revenue in HKD (TTM)18.97bn
- Net income in HKD1.01bn
- Incorporated1992
- Employees17.30k
- LocationChina Traditional Chinese Medicine Holdings Co LtdRoom 1601, Emperor Group Centre288 Hennessy RoadWanchai Hong KongHKG
- Phone+852 28543393
- Fax+852 25441269
- Websitehttps://www.china-tcm.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Luye Pharma Group Ltd | 6.96bn | 849.73m | 11.36bn | 5.27k | 13.37 | 0.7912 | 6.64 | 1.63 | 0.2259 | 0.2259 | 1.85 | 3.82 | 0.236 | 2.44 | 2.84 | 1,321,269.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 2.96 | 0.4016 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
Shanghai Henlius Biotech Inc | 6.22bn | 763.57m | 12.53bn | 3.55k | 16.45 | 4.41 | 10.70 | 2.01 | 1.40 | 1.40 | 11.40 | 5.23 | 0.5764 | 1.90 | 6.82 | 1,710,433.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 6.86 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
3SBio Inc | 9.29bn | 1.83bn | 13.65bn | 5.61k | 7.59 | 0.8539 | 6.02 | 1.47 | 0.7509 | 0.7509 | 3.81 | 6.68 | 0.3575 | 1.52 | 6.73 | 1,716,495.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 23.87 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 15.37bn | 10.78k | 6.29 | 0.9778 | 5.34 | 1.45 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 3.21 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
Simcere Pharmaceutical Group Ltd | 6.99bn | -1.22bn | 15.79bn | 7.03k | -- | 2.15 | -- | 2.26 | -0.4648 | -0.4648 | 2.72 | 2.91 | 0.5198 | 2.19 | 2.64 | 995,369.40 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4709 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
The United Laboratories Intl. Hldgs Ltd. | 15.45bn | 3.21bn | 15.83bn | 15.00k | 4.93 | 1.06 | 4.13 | 1.02 | 1.77 | 1.77 | 8.50 | 8.21 | 0.6578 | 3.30 | 3.54 | 1,030,028.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
Zai Lab Ltd | 2.52bn | -2.33bn | 16.40bn | 2.18k | -- | 2.94 | -- | 6.52 | -2.39 | -2.39 | 2.59 | 5.59 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
China Medical System Holdings Ltd | 7.74bn | 1.53bn | 19.08bn | 5.78k | 12.46 | 1.08 | 10.73 | 2.47 | 0.6276 | 0.6276 | 3.16 | 7.26 | 0.384 | 2.89 | 5.65 | 1,356,928.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
China Traditional Chinese Med Hldg CoLtd | 18.97bn | 1.01bn | 21.91bn | 17.30k | 21.65 | 0.9294 | 9.49 | 1.15 | 0.2009 | 0.2009 | 3.77 | 4.68 | 0.453 | 1.54 | 1.76 | 1,096,593.00 | 2.62 | 4.60 | 4.01 | 7.07 | 49.86 | 57.07 | 5.77 | 9.77 | 1.51 | 6.63 | 0.1808 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
HUTCHMED (China) Ltd | 4.76bn | -327.14m | 23.70bn | 1.97k | -- | 4.11 | -- | 4.98 | -0.3893 | -0.3893 | 5.52 | 6.62 | 0.4775 | 7.10 | 4.15 | 2,394,864.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
WuXi XDC Cayman Inc | 3.08bn | 655.72m | 24.22bn | 1.50k | 37.47 | 3.66 | 32.21 | 7.86 | 0.539 | 0.539 | 2.73 | 5.51 | 0.5586 | 21.31 | 2.62 | 2,617,298.00 | 11.88 | -- | 15.43 | -- | 30.96 | -- | 21.27 | -- | 4.02 | 204.82 | 0.0113 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
China Resources Pharmaceutical Group Ltd | 276.33bn | 4.16bn | 31.29bn | 72.76k | 7.51 | 0.5865 | 2.45 | 0.1132 | 0.6627 | 0.6627 | 43.98 | 8.49 | 0.966 | 6.09 | 3.00 | 3,786,016.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
Holder | Shares | % Held |
---|---|---|
Ping An of China Asset Management (Hong Kong) Co., Ltd.as of 31 Dec 2023 | 604.30m | 12.00% |
UBS Asset Management Switzerland AGas of 26 Aug 2024 | 386.60m | 7.68% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 92.71m | 1.84% |
Dimensional Fund Advisors LPas of 05 Sep 2024 | 73.72m | 1.46% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 57.20m | 1.14% |
BlackRock Fund Advisorsas of 05 Sep 2024 | 32.39m | 0.64% |
UBS Asset Management (Americas) LLCas of 26 Aug 2024 | 23.92m | 0.48% |
HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 19.11m | 0.38% |
BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 8.70m | 0.17% |
E Fund Asset Management Co. Ltd.as of 30 Jun 2024 | 8.14m | 0.16% |